

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CLARITY MEDICAL GROUP HOLDING LIMITED

### 清晰醫療集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

## INSIDE INFORMATION

### COURT APPLICATIONS INVOLVING THE COMPANY, CERTAIN OF ITS DIRECTORS AND A FORMER DIRECTOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clarity Medical Group Holding Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 22 September 2025, the Company, as a defendant, received the originating summons dated 19 September 2025 (the “**Originating Summons**”) issued at the Court of First Instance of the High Court of Hong Kong (the “**Court**”) by TSE Wai Ip as a plaintiff (the “**Plaintiff**”) against the Company under action number HCMP 1627 of 2025. The Plaintiff is a former executive Director whose office was vacated by the Board on 1 August 2025 due to disqualification events specified under Article 86(4) of the Company’s Articles of Association and the Plaintiff has also been removed at the Company’s extraordinary general meeting held on 23 September 2025 without prejudice to the validity of the Board’s determination under such Article 86(4) that his office had already been vacated.

Pursuant to the Originating Summons, the Plaintiff is applying to the Court for (1) the Court’s leave to bring proceedings on behalf of the Company against the following seven persons (collectively, the “**Potential Defendants**”), namely, JIANG Bo (an executive Director and the Chief Executive Officer of the Company, “**Mr. Jiang**”), HUI Yung Chris (an executive Director and the Co-Chief Executive Officer of the Company, “**Mr. Hui**”), WU Ting Yuk Anthony (a non-executive Director and the Chairman of the Company, “**Mr. Wu**”), WANG Can (an independent non-executive Director, “**Mr. Wang**”), ZHAO Wei (a former non-executive Director, “**Ms. Zhao**”), CI Ying (an independent non-executive Director, “**Ms. Ci**”) and United Orion Advisory Limited (“**UOA**”); (2) a Court order appointing a receiver and manager of the Company pending the determination of the application and/or the proceedings to be brought under item (1) above; (3) a Court Order appointing an independent person to investigate and report to the Court on the Company’s financial position and/or the facts or circumstances that gave rise to the application or the proceedings to be brought under item (1) above; and (4) costs to be paid by the Company.

In respect of item (1) above, the Plaintiff suggests that the Company bring proceedings against the Potential Defendants on matters involving, among other things, the acquisition by Innovative Vision Inc of the Company's shares, Mr. Hui's remuneration, the Company's agreements with UOA, the employment of certain employees, bank accounts signatories, the assignment by Dr. LAU Tsz Yan Teresa to Saintford Limited (a wholly-owned subsidiary of the Company) of her rights in the sum of HK\$1,750,000 (plus interest) owed by the Plaintiff, whistleblowers, the duties of Mr. Wu, Mr. Wang, Ms. Zhao and Ms. Ci to control the actions of Mr. Jiang and Mr. Hui, the disqualification of the Plaintiff as a Director by the Board, the utilisation of the Company's funds, and the fiduciary duties of those Potential Defendants who are Directors or former Director.

Most of the above-mentioned matters overlap with the allegations made by the Plaintiff against Mr. Jiang and/or Mr. Hui as disclosed in the Company's announcement dated 30 May 2025. Such earlier allegations are being investigated by the Special Committee of the Company with the assistance of independent professional advisers.

The Company is seeking legal advice in relation to the above-mentioned legal action initiated by the Plaintiff. Should the Company, upon receiving legal advice, consider that the action lacks merits, it will pursue a robust defence and may take necessary legal action against the Plaintiff. Further announcement(s) will be made by the Company as and when appropriate to keep its shareholders and potential investors informed of any material developments concerning the legal action.

By order of the Board  
**CLARITY MEDICAL GROUP HOLDING LIMITED**  
**WU Ting Yuk Anthony**  
*Non-Executive Director and Chairman*

Hong Kong, 23 September 2025

*As at the date of this announcement, the Board comprises Mr. JIANG Bo and Mr. HUI Yung Chris as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. CHEN Jiarong as non-executive Director, and Ms. CHENG Jessica, Mr. WANG Can and Ms. CI Ying as independent non-executive Directors.*